All Insight, Analysis and Views

ViewPoints: Amgen sets KRAS bar – now up to Mirati to raise it
Ref: ViewPoints Desk
Tags: ViewPointsAmgen Mirati TherapeuticsColorectal Cancer Lung Cancer FDAClinical Research (R&D) Marketing & Sales Medical Affairsadagrasib Lumakras
The FirstTake Podcast – 16 September 2021
Ref: ViewPoints Desk
Tags: ViewPoints Clinical Research (R&D) Licensing
Join us next week for our five key takeaways from ESMO 2021
Ref: ViewPoints Desk
Tags: ViewPointsBreast Cancer Colorectal Cancer Lung Cancer Melanoma ESMO Congress
Physician Views Results: Ophthalmologists eager to adopt Apellis’ geographic atrophy therapy despite mixed Phase III data
Ref: Physician Views Desk
Tags: Physician Views Poll ResultsApellis Pharmaceuticals Clinical Research (R&D)pegcetacoplan
Friday Five – The Pharma Week in Review (17 September 2021)
Ref: Friday Five Desk
Tags: Friday FiveAbbVie Biogen Everest Medicines Providence Therapeutics REGENXBIO Clinical Research (R&D) Licensing Marketing & SalesESMO Congress
ViewPoints: Out with old, in with new curative hopes in HIV
Ref: ViewPoints Desk
Tags: ViewPointsEditas Medicine Excision BioTherapeutics J&JAIDS and HIV FDAClinical Research (R&D)EBT-101
Physician Views: Will Apellis' geographic atrophy data convince US ophthalmologists?
Ref: Physician Views Desk
Tags: Physician ViewsApellis Pharmaceuticals Clinical Research (R&D)pegcetacoplan
Spotlight On: Five things to watch at ESMO 2021
Ref: Spotlight On
Tags: Spotlight On ESMO Congress
Physician Views Results: Novel access arrangement for Novartis' Leqvio a win-win…
Ref: Physician Views Desk
Tags: Physician Views Poll ResultsNovartisDyslipidemia Marketing & SalesLeqvio
ViewPoints: Tide may be turning against Oncopeptides' Pepaxto
Ref: ViewPoints Desk
Tags: ViewPointsOncopeptidesMyeloma FDAMarketing & Sales Medical Affairs Regulatory AffairsPepaxto